Methylergonovine maleate as a cluster headache prophylactic: A study and review

Headache

Volumn 37, Issue 7, 1997, Pages 437-442

  Mueller, Loretta ^a   Gallagher, R Michael ^a   Ciervo, Carman A ^a  

^a University Headache Center   (United States)

Author keywords

Cluster; Methylergonovine maleate; Methysergide

Indexed keywords

ERGOT DERIVATIVE; METHYLERGOMETRINE MALEATE; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLUSTER HEADACHE; DRUG EFFICACY; HEARTBURN; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORAX DISEASE;

CLUSTER HEADACHE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METHYLERGONOVINE; MOLECULAR STRUCTURE; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 0030816705     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1997.3707437.x     Document Type: Article

References (63)

1. Stoll A, Hofmann A. Alkaloids of the ergotamine group. Helv Chim Acta. 1943;26:1570.
2. Hofmann A. Historical view on ergot alkaloids. Pharmacology. 1978;16(suppl 1):1-11.
3. Berde B, Schild HO. Ergot Alkaloids and Related Compounds. New York: Springer-Verlag; 1978.
4. Müller-Schweinitzer E, Tapparelli C. Methylergometrine, an active metabolite of methysergide. Cephalalgia. 1986;6:35-41.
5. Physicians' Desk Reference. 49th ed. Oradell, NJ: Medical Economics Co, Inc; 1995:2174-2175.
6. Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen PA, Tfelt-Hansen V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol. 1986;30:75-77.
7. Tfelt-Hansen P, Jansen I, Edvinsson L. Methylergometrine antagonizes 5HT in the temporal artery. Eur J Clin Pharmacol. 1987;33:77-79.
8. 2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:120-129.
9. Tfelt-Hansen P, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen V. Kinetics of methylergometrine, the main metabolite of methysergide, in man. J Neurol. 1985;232(suppl):183.
10. Jansen I, Tfelt-Hansen P, Edvinsson L. Methylergometrine is more potent than methysergide as a 5-hydroxytryptamine receptor antagonist on human temporal arteries. Acta Pharmacol Toxicol. 1986;59(suppl 5, Pt 2):324. Abstract.
11. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. In: Mathew NT, ed. Neurologic Clinics. Philadelphia, Pa: WB Saunders; 1990;8:829-839.
12. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia. 1993;13:151-165.
13. Diamond S, Dalessio D. Migraine headache. In: Diamond S, Dalessio D, eds. The Practicing Physician's Approach to Headache. 5th ed. Baltimore, Md: Williams and Wilkins; 1992:51-79.
14. Elkind AH. Matching dosage forms to the needs of your headache patient. Headache Quarterly. 1992;3(suppl 1):16-21.
15. Graff-Radford SB, Bittar GT. The use of methylergonovine (Methergine®) in the initial control of drug-induced refractory headache. Headache. 1993;33:390-393.
16. Ott J, Neely P. Entheogenic (hallucinogenic) effects of methylergonovine. J Psychedelic Drugs. 1980;12: 165-166.
17. Saper JR, Silberstein S, Gordon CD, Hamel RL. Handbook of Headache Management. Baltimore, Md: Williams and Wilkins; 1993:35-82.
18. Rapoport AM, Sheftell FD. A comprehensive approach to headache treatment. In: Rapoport AM, Sheftell FD, eds. Headache: A Clinician's Guide to Diagnosis. Costa Mesa: PMA Publishing Corp; 1993:243-256.
19. Mathew NJ. The abortive treatment of migraine. In: Gallagher RM, ed. Drug Therapy for Headache. New York: Marcel Dekker, Inc; 1991:95-113.
20. Diamond S. Diagnosis and treatment of migraine. Headache Quarterly. 1993;4:8-14.
21. Raskin NH, Schwartz RK. Interval therapy of migraine: long-term results. Headache. 1980;20:336-340.
22. Gallagher RM. Pharmacologic treatment of cluster headache. In: Gallagher RM, ed. Drug Therapy for Headache. New York: Marcel Dekker, Inc; 1991:131-150.
23. Golden GS. Pharmacologic therapy for headaches in children. In: Gallagher RM, ed. Drug Therapy for Headache. New York: Marcel Dekker, Inc; 1991:173-181.
24. Gallagher RM. Menstrual migraine and intermittent ergonovine therapy. Headache. 1989;29:366-367.
25. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
26. Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache. 1983; 23:266-277.
27. Olesen J. Role of calcium entry blockers in the prophylaxis of migraine, Eur Neurol. 1986;25(suppl 1):72-79.
28. Cuypers J, Altenkirch H, Bunge S. Therapy of cluster headache with histamine H1 and H2 receptor antagonists. Eur Neurol. 1979;18:345-347.
29. Couch JR Jr, Ziegler DK. Prednisone therapy for cluster headache. Headache. 1978;18:219-221.
30. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache. 1981;21:1-4.
31. Mathew NT. Cluster headache. Neurology. 1992; 42(suppl 2):22-31.
32. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology. 1993;43(suppl 3):S34-S38.
33. Müller-Schweinitzer E. Medication of migraine by pro-serotonergic drugs. Cephalalgia. 1987;7(suppl 6):138-140.
34. 2 receptor antagonists and migraine therapy. J Neurol. 1991;238(suppl 1):S45-S52.
35. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin. 1990;8:801-815.
36. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157-168.
37. Raskin NH. On the origin of head pain. Headache. 1988;28:254-257.
38. Friedman AB, Elkind AH. Appraisal of methysergide in treatment of vascular headaches of migraine type. JAMA. 1963;184:125-128.
39. Curran DA, Hinterberger H, Lance JW. Methysergide. Res Clin Study Headache. 1967;1:74-122.
40. Mantyla R, Kleimola T, Kanto J. Pharmacokinetics of methylergometrine (methylergonovine) in the rabbit and man. Acta Pharmacol Toxicol. 1977;40:561-569.
41. Mantyla R, Kanto J. Clinical pharmacokinetics of methylergometrine (methylergonovine). Int J Clin Pharmacol Ther Toxicol. 1981;19:386-391.
42. Mantyla R, Kleimola T, Kanto J. Methylergometrine (methylergonovine) concentrations in the human plasma and urine, Int J Clin Pharmacol Biopharm. 1978;16:254-257.
43. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol. 1989;96:434-440.
44. Edvinsson L, Jansen I. Characterization of 5-HT receptors mediating contraction of human cerebral, meningeal and temporal arteries: target for GR 43175 in acute treatment of migraine? Cephalalgia. 1989;9(suppl 10):39-40.
45. Saxena PR, Verdouw PD. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol. 1984;82:817-826.
46. Gaudet RJ, Kessler II. Transparently blinded trials of methysergide. N Engl J Med. 1987;316:279-280.
47. Bianchine JR, Eade NR. Vasoactive substances and fibrosis. Res Clin Study Headache. 1969;2:60-85.
48. Volans GN. Migraine and drug absorption. Clin Pharmacokinet. 1978;3:313-318.
49. Carstairs LS. Headache and gastric emptying time. Proc R Soc Med. 1958;51:790-791.
50. Spaulding C, Weber S, Guerin F, D'Hallivillee P. Coronary artery spasm triggered by oral administration of methylergometrine. Lancet. 1991;338:317.
51. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
52. Maclntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT, agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87:401-405.
53. 2 receptor activation. Eur J Pharmacol. 1989;161:91-94.
54. 10 beta receptors. Circulation. 1994;90:1141-1153.
55. Golino P, Maseri A. Serotonin receptors in human coronary arteries. Circulation. 1994;90:1573-1575,
56. Igarashi Y, Yamazoe M, Shibata A. Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina. Am Heart J. 1991;121:1094-1100.
57. Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogoza JM. Reversible cerebral arteriopathy associated with the administration of ergot derivatives. Cephalalgia. 1984;4:171-178.
58. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J. 1974;88:640-655.
59. Graham JR, Suby HI, LeCompte PM, Sudowsky NL. Inflammatory fibrosis associated with methysergide therapy. Res Clin Study Headache. 1967;1:123-164.
60. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci. 1967;254:1-12.
61. Iwamura S, Kambegawa A. Determination of methylergometrine and dihydroergotoxine in biological fluids. J Pharmacobiodyn. 1981;4:275-281.
62. Erkkola R, Kanto J, Allonen H, Kleimola T, Mantyla R. Excretion of methyergometrine (methylergonovine) into the human breast milk. Int J Clin Pharmacol Biopharm. 1978;16:579-580.
63. Lipton RB, Micieli G, Russell D, Solomon S, Tfelt-Hansen P, Waldenlind E. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia. 1995; 15:452-462.